Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Raw Materials (2016 - 2019)

Aptevo Therapeutics' Raw Materials history spans 5 years, with the latest figure at $491000.0 for Q4 2019.

  • For Q4 2019, Raw Materials rose 153.09% year-over-year to $491000.0; the TTM value through Dec 2019 reached $491000.0, up 153.09%, while the annual FY2019 figure was $491000.0, 153.09% up from the prior year.
  • Raw Materials for Q4 2019 was $491000.0 at Aptevo Therapeutics, down from $640000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $7.6 million in Q2 2016 and bottomed at $43000.0 in Q3 2018.
  • The 5-year median for Raw Materials is $244500.0 (2017), against an average of $1.4 million.
  • The largest annual shift saw Raw Materials plummeted 96.74% in 2017 before it skyrocketed 1388.37% in 2019.
  • A 5-year view of Raw Materials shows it stood at $6.5 million in 2015, then crashed by 96.01% to $260000.0 in 2016, then crashed by 78.46% to $56000.0 in 2017, then surged by 246.43% to $194000.0 in 2018, then skyrocketed by 153.09% to $491000.0 in 2019.
  • Per Business Quant, the three most recent readings for APVO's Raw Materials are $491000.0 (Q4 2019), $640000.0 (Q3 2019), and $612000.0 (Q2 2019).